Navigation Links
DuoCort AB: DuoCort announces Phase I Data Presentation at the,European Congress of Endocrinology

HELSINGBORG, Sweden--(BUSINESS WIRE)--Apr 25, 2007 - DuoCort AB today announced that results of the Phase I trial of its 5 mg and 20 mg dual release hydrocortisone tablets for adrenal insufficiency will be presented at the 9th European Congress of Endocrinology on April 30 in Budapest. The trial evaluated the safety and pharmacokinetics of the new hydrocortisone tablets in healthy volunteers.

The Phase I study showed that both the DuoCort 5 mg and 20 mg hydrocortisone dual-release tablets were safe and well tolerated. The novel dual-release formulation showed a rapid increase in cortisol levels after single-dose administration, the dose was well absorbed and it had similar bioavailability to the oral hydrocortisone in the literature. Moreover, the data showed no risk of dose accumulation. The release profile closely resembled the physiological one, including the natural nocturnal cortisol free interval.

Based on the promising Phase I data, DuoCort is now launching its Phase II / III program. "We are very pleased with the outcome of the Phase I trial, especially as there was very little inter- or intra-individual variability in the pharmacokinetics and the drug release profiles look very like the physiological release profile of cortisol in healthy individuals," said DuoCort's Chief Medical Officer, Dr Gudmundur Johannsson. "The Phase II trial will seek to demonstrate similar safety, tolerability and pharmacokinetics in patients, as well as gathering other safety and quality of life data."

About dual-release hydrocortisone

DuoCort's dual-release 5 mg and 20 mg hydrocortisone tablets for patients with chronic adrenal insufficiency were granted an Orphan Medicinal Product Designation in the European Union in May 2006. DuoCort's objective is to improve today's glucocorticoid replacement therapy with a once-daily tablet which is more convenient than current treatment and capable of improving pat
'"/>




Page: 1 2

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/30/2014)... , September 30, 2014 ... report the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, ... Kits, and Reagents], Application (Immunology, Oncology) & ... 2019", published by MarketsandMarkets, provides a detailed ... opportunities, current market trends, and strategies impacting ...
(Date:9/30/2014)... 30, 2014   Easy Breathe , the fastest ... announced that it now offers the revolutionary AirSense ... the first sleep apnea therapy devices with internal cellular ... to track and share real-time data on each user,s ... CPAP therapy.  In addition, the internal modem allows the ...
(Date:9/30/2014)... 30, 2014 The Chinese wound care market ... rise in the incidence of lifestyle diseases, coupled with ... affordability of better quality of wound care products provide ... coverage of public health insurance schemes and increased reimbursement ... Based on the findings of primary and secondary researches, ...
Breaking Medicine Technology:Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4China Wound Care Market 2China Wound Care Market 3
... BRUNSWICK, N.J., Sept. 30 Savient Pharmaceuticals, Inc. (Nasdaq: ... Court for the Southern District of New York has dismissed ... captioned Richard Sagall vs. Savient Pharmaceuticals, Inc., et al. ... The suit alleged that the Company made false and misleading ...
... HHS, Agency for Healthcare Research and Quality today ... contracts to support projects that will help people make ... effectiveness. The funding announced today covers all of AHRQ,s ... by AHRQ.   The projects will support ...
Cached Medicine Technology:Savient Pharmaceuticals Announces Dismissal of Class Action Lawsuit 2HHS Awards $473 Million in Patient-Centered Outcomes Research Funding 2
(Date:10/1/2014)... Insuranceragents.info has released a new blog post explaining how ... family members. , Life insurance plans provide important financial ... should always carry a life insurance policy as their ... the family. , Clients can choose from several ... coverage or from a permanent policy. No medical exam ...
(Date:10/1/2014)... ATLANTA (PRWEB) October 01, 2014 ... executive networking and relationship-marketing firm, announced today ... Security Executive® and Project of the Year ... decision makers representing organizations in financial services, ... include large-scale technology endeavors that address key ...
(Date:10/1/2014)... Between 23 million and 50 million ... to figures from the National Institutes of Health (NIH) ... many of them have something else in common: They ... disease. Gluten Free Therapeutics, makers of CeliVites ... disease by publishing a series of blog posts aimed ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Scientists at ... three drugs that target immune system proteins has the ... has just posted details of the new study on ... now. , Researchers in the UWA School of ... anti-CTLA-4 drugs to mice with mesothelioma with promising results. ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Woodland ... speak to a group of dental specialists who treat ... northern Spain city of Oviedo. Dr. Reshad of the ... lecturer with clients on two continents, will give a ... aesthetic full mouth reconstruction. , “These specialists want to ...
Breaking Medicine News(10 mins):Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 3Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 4
... the combination of chemotherapy with a new medication could ... the study of close to 1,000 patients, the overall ... chemotherapy and the oral drug uracil-tegafur. Results of the ... died within five years compared to 89 patients who ...
... Researchers say , the leading cause of blindness for ... macular degeneration // is the leading cause of blindness ... causes of blindness for blacks. ,More than 50 ... because of macular degeneration. In contrast, more than 60 ...
... Americans undergo balloon angioplasty to clear blocked arteries. In many ... may change the outcome of the procedure. ,John ... to avoid a second open-heart surgery. Eight years ago, he ... this year, Bailey had the same kind of chest pain. ...
... on the results of a recent study researchers offer ... of stretching before exercising.// Specialists say stretching does not ... shows static stretching makes muscles weaker for 10 to ... injury. They say some likely causes of injuries include ...
... Diabetic retinopathy is one of the leading causes of blindness ... the retina and the light-sensitive // layer of cells at ... with long-standing diabetes but its incidence can be reduced with ... shows approximately 4.1 million Americans, age 40 or older, suffer ...
... to offer good news for older adults .The first ... in the elderly. Researchers studied nearly 140 adults over ... major depression, while the other half suffered from minor ... had an annual income of less than $10,000. ...
Cached Medicine News:
... Our Shortest, Lightest Pipettor , , The ... perfect example of how our face-to-face relationship with ... new products that make pipetting easier and more ... single channel pipettors., Gets you closer to ...
Single channel module for Finnpipette Biocontrol - Universal handle sold separately...
... The Research pro Electronic Pipette is ideal ... laboratory. Its easy-to-follow display, ergonomically-placed operating buttons, ... dispensing, reverse pipetting and diluting make this ... simple functions of a manual pipette without ...
Inquire...
Medicine Products: